Karyopharm Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

KPTI$0.04-27.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2026	2025	2026	2025
Revenues:
Product revenue, net	$30,776	$29,681	$59,939	$50,735
License and other revenue	2,656	8,248	8,559	17,209
Total revenue	33,432	37,929	68,498	67,944
Operating expenses:
Cost of sales	1,085	1,051	2,430	2,352
Research and development	28,957	32,788	62,754	67,406
Selling, general and administrative	25,916	28,477	52,600	55,829
Total operating expenses	55,958	62,316	117,784	125,587
Loss from operations	(22,526)	(24,387)	(49,286)	(57,643)
Other income (expense):
Interest income	722	613	1,233	1,613
Interest expense	(13,144)	(11,228)	(25,697)	(22,222)
Other (expense) income, net	(32,075)	(2,210)	(15,664)	17,614
Total other expense, net	(44,497)	(12,825)	(40,128)	(2,995)
Loss before income taxes	(67,023)	(37,212)	(89,414)	(60,638)
Income tax provision	—	(40)	(1)	(76)
Net loss	$(67,023)	$(37,252)	$(89,415)	$(60,714)
Basic and diluted net loss per share	$(2.32)	$(4.32)	$(3.51)	$(7.11)
Weighted-average number of common shares outstanding used to compute basic and diluted net loss per share	28,938	8,620	25,495	8,545

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.